I am sure this has been discussed before, but I just came across this recently, so I thought I would canvass all the science experts on this board.

This poster says that in Phase 2, RVX208 statistically significantly reduced Alkaline Phosphatase and statistically significantly increased eGFR.  Leaving aside MACE relative risk reduction, these 2 seem to be as just a powerful an outcome as one could hope for.  The only issue I see is that the number of patients who took the drug is a bit on the low side.

I am sure all this has been discussed on this board...but can someone please enlighten me on what the conclusions were?  In my books, if eGFR is being raised and ALP reduced, that is about as good a result as one can hope for.

Thanks!

https://www.resverlogix.com/upload/media_element/attachments/20/ASN%202015%20Poster%20(1).pdf